Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 10819.145 | 0.9389 | 0.9434 | 2.1971 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 10819.145 | 0.9837 | 0.9851 | 2.1971 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 10819.145 | 0.9900 | 0.9908 | 2.1971 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 10819.145 | 1.0003 | 1.0003 | 2.1971 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 10819.145 | 1.0071 | 1.0065 | 2.1971 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 10819.145 | 0.9455 | 0.9496 | 2.1971 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 10819.145 | 0.9853 | 0.9866 | 2.1971 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 10819.145 | 1.0107 | 1.0097 | 2.1971 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 11937.145 | 1.0320 | 1.0268 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 11937.145 | 0.9434 | 0.9512 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 11937.145 | 1.0145 | 1.0122 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 11937.145 | 1.0318 | 1.0267 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 11937.145 | 1.0180 | 1.0151 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 11937.145 | 1.0616 | 1.0512 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 11937.145 | 0.5154 | 0.5105 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 11937.145 | 0.6668 | 0.6846 | 2.3618 | |
| SUM149PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 11937.145 | 0.3909 | 0.3437 | 2.3618 | |
| SUM159PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 11057.145 | 1.0979 | 1.0494 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 11057.145 | 1.0087 | 1.0046 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 11057.145 | 1.0498 | 1.0256 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 11057.145 | 1.1642 | 1.0811 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 11057.145 | 0.9897 | 0.9946 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 11057.145 | 1.0904 | 1.0458 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 11057.145 | 0.8686 | 0.9277 | 3.8266 | |
| SUM159PT | TNBC | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 11057.145 | 1.0756 | 1.0385 | 3.8266 |